Drug Hypersensitivity Syndrome Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 24, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Drug Hypersensitivity Syndrome. It connects disease context, epidemiology, target mechanism, clinical competition, transactions, unmet need and market attractiveness for portfolio and partnering decisions.

Executive assessment

Drug Hypersensitivity Syndrome receives a directional strategic score of 69/100, combining unmet need (83/100), competitive intensity (63/100, where higher means more competition) and market attractiveness (75/100). The score is a transparent prioritization aid, not a revenue forecast, clinical recommendation or investment conclusion.

Disease background and strategic definition

Severe drug eruption characterized by high fever, erythematous rash and inflammation of internal organ(s).

The reproducible entity is Patsnap disease ID f74b1b35ec814aa996b5b51a51bd2d6c with MeSH identifier D063926. Stable identifiers are important because rare and precision-defined diseases often carry historical labels, gene-defined subtypes and overlapping syndromic names.

A credible target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, treatment setting, acceptable safety and endpoint. A broad label may inflate theoretical market size while weakening biological signal, trial interpretability and recruitment feasibility. The first population should be narrow enough for coherent biology but large enough for execution.

The care pathway should be mapped from symptom recognition through referral, diagnostic testing, treatment initiation and longitudinal monitoring. Diagnostic delay, limited specialist centers and fragmented testing can constrain both trial enrollment and commercial access. These bottlenecks deserve explicit operational assumptions.

Epidemiology and disease burden

Epidemiology evidence 1: Incidence and prevalence of autoimmune diseases in China: A systematic review and meta-analysis of epidemiological studies

Due to the difference in the magnitude of estimates between condi­ tions, we grouped conditions into “low prevalence” (CD, UC, IBD, MS, T1D and SLE) and “high prevalence” (RA, GD and AT) groups, based on whether the pooled estimates were lower than 100 per 100,000 persons, or greater, respectively. For CD and UC, the fixed-effects pooled esti­ mates were 3.73 (95% CI 3.68–3.78), 16.11 (15.93–16.29) and random- effects estimates were 3.40 (0.50–22.92) and 12.59 (4.46–35.55) per 100,000 persons, respectively, based on four studies covering Taiwan, Hong Kong and mainland China (Fig. 3) [26,27,37,38]. Several other studies were identified but were excluded due to partial overlap or insufficient data (Supplementary Table 3). The Hong Kong studies, [27] which used active case finding had higher prevalence than the Taiwan[26,39] and mainland China studies, [37,38] which did not. For MS (7 estimates; 7 studies) the pooled estimates were 4.08 (3.95–4.21) and 2.45 (1.40–4.29) per 100,000 persons in the fixed-effects and random-effects models, respectively [33,40–45]. One prevalence esti­ mate was identified for T1D of 47.90 (95% CI 47.01–48.79) per 100,000 persons in Taiwan [46]. For SLE (6 estimates; 6 studies) the pooled es­ timates were 93.44 (92.27–94.63) and 60.30 (41.28–88.08) per 100,000 persons in the fixed-effects and random-effects models, respectively [47–52]. Except for SLE, where two of the studies were based on survey data, all other estimates in the “low prevalence” group were based on Fig. 2. Incidence of autoimmune diseases.

Review the epidemiology source

Epidemiology evidence 2: Paraneoplastic autoimmune Laminin-332 syndrome (PALS): Anti-Laminin-332 mucous membrane pemphigoid as a prototype Autoimmunity Reviews Paraneoplastic autoimmune Laminin-332 syndrome (PALS): Anti-Laminin-332 mucous membrane pemphigoid as a prototype

To substantiate evidence to support the proposed syndrome, relevant articles were comprehensively and systematically identified from the online databases PubMed, Embase and others, published up to June 2023. The search included the following keywords in combination with Medical Subject Headings (MeSH), terms and text words: Laminin-332, Anti-epiligrin, Laminin 5, Mucous Membrane Pemphigoid, Systemic Lupus Erythematosus, Psoriasis, Psoriasis Vulgaris, Bronchiolitis Oblit­ erans, Epidermolysis Bullosa Acquisita, Membranous Glomerulone­ phropathy, Membranous Nephropathy, Systemic Sclerosis, Scleroderma, Dermatomyositis, Immune Polymyositis, Multiple Sclerosis, Immune Thrombocytopenia Purpura, Immune Thrombocytopenia, Rheumatoid Arthritis, Neoplasia, Neoplasias, Neoplasm, Tumor, Tumors, Tumour, Tumours, Cancer, Cancers, Malignant Neoplasm, Malignant Neoplasms, Malignancy, and Malignancies. The following data was retrieved, if available: (i) autoimmune diseases with autoantibodies to Laminin-332 and (ii) cancer incidence in these autoimmune diseases. Pooled standardized incidence rates (SIRs), relative risks (RRs), odds ratios (ORs), and morbidity rates (MRs) with 95% confidence intervals (CIs) were utilized to clarify the correlations between the autoimmune disease and malignancy. 2.2. Inclusion/exclusion criteria

Review the epidemiology source

Epidemiology evidence 3: Global, regional, and national burden of autoimmune disease in older adults (≥60 years) from 1990 to 2021: Results from the Global Burden of Disease Study 2021

### Chart Data Transcription Report 1. Basic Chart Information * Chart Title: Regional incidence and ASIR of the 5 autoimmune diseases in 2021. * Chart Type: Comparative Data Table * Contextual Summary: This table presents the regional incidence and age-standardized incidence rates (ASIR) for five autoimmune diseases (Rheumatoid Arthritis, Inflammatory Bowel Disease, Multiple Sclerosis, Type 1 Diabetes Mellitus, and Psoriasis) across various locations and SDI levels in 2021. 2. Chart Structure and Elements * Axes/Headers: * Row Headers: Location (Global, High SDI, High-middle SDI, Middle SDI, Low-middle SDI, Low SDI, Andean Latin America, Australasia, Caribbean, Central Asia, Central Europe, Central Latin America, Central Sub-Saharan Africa, East Asia, Eastern Europe, Eastern Sub-Saharan Africa, High-Income Asia Pacific, High-Income North America, North Africa and Middle East) * Column Headers: * RA (Rheumatoid Arthritis): Incidence (95% UI), ASIR (1/100,000, 95% UI) * IBD (Inflammatory Bowel Disease): Incidence (95% UI), ASIR (1/100,000, 95% UI) * MS (Multiple Sclerosis): Incidence (95% UI), ASIR (1/100,000, 95% UI) * T1DM (Type 1 Diabetes Mellitus): Incidence (95% UI), ASIR (1/100,000, 95% UI) * Psoriasis: Incidence (95% UI), ASIR (1/100,000, 95% UI) * Legend/Groups: Not applicable. The table directly presents data for each disease by location. * Notes and Footnotes: (continued on next page) 3. Detailed Data Transcription This table presents the regional incidence and age-standardized incidence rates (ASIR) for Rheumatoid Arthritis (RA), Inflammatory Bowel Disease (IBD),

Review the epidemiology source

Translate epidemiology into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence cannot be substituted for one another, and incompatible case definitions should not be pooled.

For Drug Hypersensitivity Syndrome, quantify diagnostic yield, age and severity distribution, referral-center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges. Each parameter should have a source, access date and explanation of how it maps to the intended clinical population.

Population concentration can materially change strategy. A small but well-defined group managed in a limited number of centers may be operationally attractive, while a larger but poorly diagnosed population may require extensive testing and education. Epidemiology must therefore connect to the real patient journey.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: irreversible progression, incomplete control, treatment-limiting toxicity, weak durability, burdensome administration, delayed diagnosis or lack of options for a biomarker-defined subgroup. Disease severity alone does not prove that a new program can demonstrate clinically meaningful benefit.

A strong Drug Hypersensitivity Syndrome thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Functional measures, patient-reported outcomes and resource use may complement biomarkers.

Development should proceed through evidence gates. Establish phenotype and natural history, demonstrate target engagement, observe a pharmacodynamic response, show an interpretable clinical signal and only then scale toward registrational development. Pre-agreed stop criteria protect capital and improve learning from negative results.

Target mechanism anchor: IL-1β

Potent pro-inflammatory cytokine (PubMed:10653850, PubMed:12794819, PubMed:28331908, PubMed:3920526). Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production (PubMed:3920526). Promotes Th17 differentiation of T-cells. Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells (PubMed:10653850). Plays a role in angiogenesis by inducing VEGF production synergistically with TNF and IL6 (PubMed:12794819). Involved in transduction of inflammation downstream of pyroptosis: its mature form is specifically released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed:33377178, PubMed:33883744). Acts as a sensor of S.pyogenes infection in skin: cleaved and activated by pyogenes SpeB protease, leading to an inflammatory response that prevents bacterial growth during invasive skin infection (PubMed:28331908).

The mechanism anchor is IL1B. It is a pathway hypothesis, not a claim that every Drug Hypersensitivity Syndrome patient is target-dependent. Translational work should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and a therapeutic window.

Critical experiments include orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit on-target and off-target safety testing. Human evidence should carry greater weight than model-only observations. Related clinical failures should be examined for exposure, population and endpoint lessons.

A go decision requires a complete chain: relevant target biology, achievable modulation at tolerated exposure, measurable pharmacodynamic change and a plausible bridge to clinical benefit. Missing links should trigger targeted experiments rather than narrative confidence.

Clinical development and competitive landscape

The focused query returned 26 registered studies. Recent sampled records include:

• ACTRN12626000186358 — BIOmarkers for the evaluation of patients with DRESS syndrome using skin tape STRIPs: BIO-STRIP study; Not yet recruiting; Not Applicable; sponsor Sir Charles Gairdner Hospital; enrollment 42.
• JPRN-jRCT1050250064 — Elucidation of the mechanisms of intractable immune-mediated diseases using iPS cell-derived organoid models; 募集前; Not Applicable; sponsor not stated; enrollment 60.
• ChiCTR2500104892 — Drug Hypersensitivity Syndrome Comorbid with Acute Clonorchiasis: A Case Report; Not yet recruiting; Not Applicable; sponsor Foshan Chinese Traditional Medicine Hospital; enrollment 1.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies from one asset can inflate activity. Normalize every record by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy should compare against the likely future standard at launch. Whitespace can arise from earlier treatment, genotype selection, improved durability, lower monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim must be visible in protocol design, not deferred to post hoc interpretation.

Recruitment risk is a core strategic variable. Site density, diagnostic testing, travel burden, competing protocols and screen-failure rates should inform country and center selection. Natural-history work can reduce uncertainty but cannot replace a controlled efficacy strategy when outcomes are variable.

Transaction activity and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This may reflect limited partnering, broader transaction labels or asset-level indexing. Add target- and asset-based comparable searches before valuation.

Headline transaction value is rarely directly comparable. Separate upfront payments, milestones, royalties, options, bundled programs, platform rights and geographic scope. A useful comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual property, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that retires material risk.

Low direct deal activity can represent whitespace, but it can also signal difficult science or economics. Broader therapeutic-area transactions should be used only when their relevance is explicit. Avoid assuming that all rare-disease transactions share the same valuation logic.

Market attractiveness and access

Market attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, alternatives, monitoring burden and geographic reimbursement. Patient count is only one driver. Reliable identification and a meaningful effect may outweigh a small population; fragmented diagnosis can undermine a larger one.

The commercial model should use scenario ranges for diagnosed prevalence, eligible share, launch timing, competitive entries, net price, persistence and penetration. Every assumption should be traceable. Refresh the model when new epidemiology, trial or deal evidence becomes available.

Payer research should begin before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Evidence may need quality of life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The value proposition should connect clinical effect to stakeholder-relevant outcomes.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate IL1B relevance in the selected phenotype.
• Translation risk: connect engagement to a biomarker and meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing and screen-failure assumptions.
• Commercial risk: test pricing, access and adoption with clinicians and payers.
• Data risk: treat zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are population confirmation, human mechanism validation, differentiated target product profile, early proof of mechanism and scale-up only after biological, clinical, operational and commercial signals converge.

Strategic recommendation

Drug Hypersensitivity Syndrome merits continued milestone-based evaluation. The opportunity is strongest if a phenotype or biomarker identifies patients with coherent biology, if IL1B modulation is measurable and if the proposed benefit remains differentiated against future care. Current evidence supports targeted diligence rather than unconditional investment.

The near-term business-development objective is a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard offers a common comparison language while preserving evidence gaps and uncertainty.

Methodology and source note

This report was assembled on August 24, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update.

Ranking weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio commitment.

Conclusion

The key question for Drug Hypersensitivity Syndrome is whether a biologically grounded therapy can deliver material patient benefit in an identifiable population and remain differentiated through launch. The evidence assembled here supplies a structured starting point, while the explicit gaps define the next diligence plan.